文献速递乳腺癌放疗

HER-2阳性乳腺癌放疗降强化:是否需瘤床加量?

De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-08-28

本研究基于HERA试验中1082例接受保乳手术、全乳放疗及曲妥珠单抗辅助化疗的HER-2阳性乳腺癌患者,分析放疗瘤床加量对局部控制的影响。

要点

  • HER-2阳性乳腺癌保乳术后全乳放疗加曲妥珠单抗治疗局部控制率优秀。
  • 年龄<40岁及不同激素受体亚组中,加量均未显著降低局部复发风险。

核心结论

  • HER-2阳性乳腺癌患者接受保乳手术、全乳放疗及曲妥珠单抗治疗后局部控制优秀,额外放疗加量未显示改善局部控制。

研究设计与样本

  • 研究纳入原HERA试验中1082例接受保乳手术、放疗及曲妥珠单抗辅助化疗的HER-2阳性乳腺癌患者,比较放疗加量与否对局部复发的影响。

主要发现

  • 441例(40.8%)接受放疗加量,641例(59.2%)未接受加量,两组年龄、淋巴结受累及分级基线特征相似。
  • 年龄<40岁患者局部复发风险较高,但加量未显著降低该风险。

临床怎么用

  • 对于接受保乳手术、全乳放疗及曲妥珠单抗治疗的HER-2阳性乳腺癌患者,可考虑省略放疗瘤床加量,以避免过度治疗。
  • 年龄<40岁或不同激素受体状态患者中,加量未显示局部控制获益,决策时需结合个体情况。

局限性

  • 研究为回顾性分析原HERA试验人群,未来需前瞻性研究识别可从放疗加量中获得临床相关获益的HER-2阳性亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy is fundamental in the management of breast cancer. After whole breast irradiation, an additional boost dose is often applied to the primary tumor bed. Here, we analyze the effect of radiation therapy boost on local control in patients with HER-2 positive breast cancer. METHODS AND MATERIALS: We studied 1082 patients with HER-2 positive breast cancer who were originally enrolled in the Herceptin Adjuvant Trial and treated with breast-conserving surgery, radiation therapy, and adjuvant chemotherapy with trastuzumab. The primary endpoint of the study was to determine the effect of a radiation boost on local recurrence. Kaplan-Meier curves were generated, and hazard ratios were estimated using Cox regression. RESULTS: Our analysis included 441 patients (40.8%) who received radiation therapy boost and 641 patients (59.2%) who did not, after completion of whole breast radiation. Patients from both groups had similar baseline characteristics in terms of age, nodal involvement, and grade. At a median follow-up of 11 years, local control was 93% (confidence interval, 90%-95%) in the radiation boost group compared with 91% (confidence interval, 89%-93%) in the no-boost group (P = .33). When analyzing patients by age, patients <40 years of age had a higher risk for local recurrence; however, this was not significantly lowered by the addition of boost. Furthermore, no local control benefit for boost was noted in both hormone receptor (HR) subtypes (HR+: P = .11; HR-: P = .98). CONCLUSIONS: Patients with HER-2 positive breast cancer treated with breast-conserving surgery, whole breast radiation, and trastuzumab have excellent local control. Delivery of an additional radiation boost in this patient population was not shown to improve local control. Future studies are needed to identify subgroups of HER-2 positive patients who derive a clinically relevant benefit from radiation boost.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Abi Jaoude J, Kayali M, de Azambuja E, et al. De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost? Int J Radiat Oncol Biol Phys. 2020. PMID: 32861819. doi:10.1016/j.ijrobp.2020.06.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。